{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:58:54Z","timestamp":1785441534700,"version":"3.56.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","award":["77380"],"award-info":[{"award-number":["77380"]}],"id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12512-4","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:51:23Z","timestamp":1785394283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Determinants of response to neoadjuvant chemotherapy in breast cancer: Integrated roles of immune pathways, DNA damage response, and cell cycle regulators"],"prefix":"10.1007","volume":"53","author":[{"given":"Danial","family":"Ahdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solmaz","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysan","family":"Gholami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima Mansoori","family":"Derakhshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"issue":"3","key":"12512_CR1","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s10549-008-0025-2","volume":"114","author":"MTA Schegerin","year":"2009","unstructured":"Schegerin MTA, Kaufman PA, Paulsen KD, Pogue BW (2009) Prognostic imaging in neoadjuvant chemotherapy of locally-advanced breast cancer should be cost-effective. Breast Cancer Res Treat 114(3):537\u2013547. https:\/\/doi.org\/10.1007\/s10549-008-0025-2 Epub 2008 Apr 25. PMID: 18437559; PMCID: PMC2807135","journal-title":"Breast Cancer Res Treat"},{"key":"12512_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.21037\/tbcr-23-50","volume":"5","author":"KR Pawloski","year":"2024","unstructured":"Pawloski KR, Barrio AV (2024) Breast surgery after neoadjuvant systemic therapy. Transl Breast Cancer Res 5:13","journal-title":"Transl Breast Cancer Res"},{"issue":"15","key":"12512_CR3","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/cncr.29348","volume":"121","author":"SSSP Mougalian","year":"2015","unstructured":"Mougalian SSSP, Killelea BK, Lannin DR, Abu-Khalaf MM, DiGiovanna MP, Sanft TB, Pusztai L, Gross CP, Chagpar AB (2015) Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer 121(15):2544\u20132552. https:\/\/doi.org\/10.1002\/cncr.29348 Epub 2015 Apr 22. PMID: 25902916","journal-title":"Cancer"},{"key":"12512_CR4","doi-asserted-by":"publisher","unstructured":"Cortazar PZL, Untch M, Mehta K et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384(9938):164 \u2013 72. https:\/\/doi.org\/10.1016\/S0140-6736(18)32772-7","DOI":"10.1016\/S0140-6736(18)32772-7"},{"key":"12512_CR5","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer. J Clin 74:229\u2013263","journal-title":"J Clin"},{"key":"12512_CR6","doi-asserted-by":"crossref","unstructured":"Shaath H, Elango R, Alajez NM (2021) Molecular Classification of Breast Cancer Utilizing Long Non-Coding RNA (lncRNA) Transcriptomes Identifies Novel Diagnostic lncRNA Panel for Triple-Negative Breast Cancer. Cancers 13(21):5350.","DOI":"10.3390\/cancers13215350"},{"key":"12512_CR7","doi-asserted-by":"crossref","unstructured":"Shatha AbuHammad MZ (2013) Gene expression alterations in doxorubicin resistant MCF7 breast cancer cell line. Genomics 101(1):213\u2013220","DOI":"10.1016\/j.ygeno.2012.11.009"},{"key":"12512_CR8","doi-asserted-by":"crossref","unstructured":"Van Nes JGPH, Julien JP, Tubiana-Hulin M, Van de Vijver M, Bogaerts J, De Vos M, Van de Velde CJ (2009) Cooperating Investigators of the EORTC www.eortc.be. Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902. Breast cancer research and treatment 115(1):101 \u2013 13","DOI":"10.1007\/s10549-008-0050-1"},{"issue":"14","key":"12512_CR9","doi-asserted-by":"publisher","first-page":"7517","DOI":"10.3390\/ijms25147517","volume":"25","author":"KGS Dvir","year":"2024","unstructured":"Dvir KGS, Leone JP (2024) Immunotherapy in Breast Cancer. Int J Mol Sci 25(14):7517. https:\/\/doi.org\/10.3390\/ijms25147517 PMID: 39062758; PMCID: PMC11276856","journal-title":"Int J Mol Sci"},{"issue":"3","key":"12512_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.21037\/cco.2020.01.06","volume":"9","author":"T Iwamoto","year":"2020","unstructured":"Iwamoto T, Kajiwara Y, Zhu Y, Iha S (2020) Biomarkers of neoadjuvant\/adjuvant chemotherapy for breast cancer. Chin Clin Oncol 9(3):27","journal-title":"Chin Clin Oncol"},{"issue":"10","key":"12512_CR12","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1080\/14737159.2022.2139602","volume":"22","author":"JT J\u00f8rgensen","year":"2022","unstructured":"J\u00f8rgensen JT, Westergaard N (2022) Predictive biomarkers and personalized pharmacotherapy. Expert Rev Mol Diagn 22(10):919\u2013922","journal-title":"Expert Rev Mol Diagn"},{"key":"12512_CR13","doi-asserted-by":"crossref","unstructured":"Guevara-Nieto H, Parra-Medina R, Orozco C, D\u00edaz-Casas S, Garai J, Zabaleta J et al (2025) Identification of predictive pretreatment biomarkers for neoadjuvant chemotherapy response in Latino invasive breast cancer patients. Mol Med 31","DOI":"10.1186\/s10020-025-01338-8"},{"issue":"2","key":"12512_CR14","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s41416-021-01328-7","volume":"125","author":"FTS L\u00fc\u00f6nd","year":"2021","unstructured":"L\u00fc\u00f6nd FTS, Christofori G (2021) Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression. Br J Cancer 125(2):164\u2013175. https:\/\/doi.org\/10.1038\/s41416-021-01328-7 Epub 2021 Apr 6. PMID: 33824479; PMCID: PMC8292450","journal-title":"Br J Cancer"},{"issue":"4","key":"12512_CR15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/gcc.2870140402","volume":"14","author":"I Bi\u00e8che","year":"1995","unstructured":"Bi\u00e8che I, Lidereau R (1995) Genetic alterations in breast cancer. Genes Chromosom Cancer 14(4):227\u2013251","journal-title":"Genes Chromosom Cancer"},{"issue":"8","key":"12512_CR16","doi-asserted-by":"publisher","first-page":"e2888","DOI":"10.1371\/journal.pone.0002888","volume":"3","author":"APLM Morel","year":"2008","unstructured":"Morel APLM, Thomas C, Hinkal G, Ansieau S, Puisieux A (2008) Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 3(8):e2888. https:\/\/doi.org\/10.1371\/journal.pone.0002888 PMID: 18682804; PMCID: PMC2492808","journal-title":"PLoS ONE"},{"issue":"6","key":"12512_CR17","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.21037\/gs-22-234","volume":"11","author":"D Fang","year":"2022","unstructured":"Fang D, Li Y, Li Y, Chen Y, Huang Q, Luo Z et al (2022) Identification of immune-related biomarkers for predicting neoadjuvant chemotherapy sensitivity in HER2 negative breast cancer via bioinformatics analysis. Gland Surg 11(6):1026\u20131036","journal-title":"Gland Surg"},{"key":"12512_CR18","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.3389\/fonc.2020.01397","volume":"10","author":"DBC Chen","year":"2020","unstructured":"Chen DBC, Zhao F, Yu H, Zhong G, Xu L, Yan S (2020) Exploring Specific miRNA-mRNA Axes With Relationship to Taxanes-Resistance in Breast Cancer. Front Oncol 10:1397. https:\/\/doi.org\/10.3389\/fonc.2020.01397 PMID: 32974144; PMCID: PMC7473300","journal-title":"Front Oncol"},{"issue":"1","key":"12512_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-025-02495-4","volume":"24","author":"A Ruiz-Iglesias","year":"2025","unstructured":"Ruiz-IglesiasA, Guilbaud E, Galluzzi L, Ma\u00f1es S (2025) Context-dependent impact of type I interferon signaling in cancer. Mol Cancer 24(1):1\u20136. https:\/\/doi.org\/10.1186\/s12943-025-02495-4","journal-title":"Mol Cancer"},{"key":"12512_CR20","doi-asserted-by":"publisher","unstructured":"Ogony JCH, Lui A, Cristofanilli M, Lewis-Wambi J (2016) Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner. Breast Cancer Res 18(1):25. https:\/\/doi.org\/10.1186\/s13058-016-0683-7","DOI":"10.1186\/s13058-016-0683-7"},{"issue":"47","key":"12512_CR21","doi-asserted-by":"publisher","first-page":"18490","DOI":"10.1073\/pnas.0809242105","volume":"105","author":"RRIH Weichselbaum","year":"2008","unstructured":"Weichselbaum RRIH, Yoon T, Nuyten DS, Baker SW, Khodarev N, Su AW, Shaikh AY, Roach P, Kreike B, Roizman B, Bergh J, Pawitan Y, van de Vijver MJ, Minn AJ (2008) An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A 105(47):18490\u201318495. https:\/\/doi.org\/10.1073\/pnas.0809242105 Epub 2008 Nov 10. PMID: 19001271; PMCID: PMC2587578","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"47","key":"12512_CR22","doi-asserted-by":"publisher","first-page":"18490","DOI":"10.1073\/pnas.0809242105","volume":"105","author":"Weichselbaum","year":"2008","unstructured":"Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DSA, Baker SW, Khodarev N et al (2008) An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci 105(47):18490\u201318495","journal-title":"Proc Natl Acad Sci"},{"key":"12512_CR23","doi-asserted-by":"crossref","unstructured":"Jacobo Jacobo MDH, Sobti S, Kaushik S, Goga A, Bandyopadhyay S (2024) An inflamed tumor cell subpopulation promotes chemotherapy resistance in triple negative breast cancer. Scientific Reports 14(1):3694","DOI":"10.1038\/s41598-024-53999-w"},{"key":"12512_CR24","doi-asserted-by":"crossref","unstructured":"Xinran Liu QM, Zhao Jia C, Zou K, Huang (2025) The multifaceted roles of ISG15 in cancer: Conjugated and free forms, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1880(1):189473","DOI":"10.1016\/j.bbcan.2025.189473"},{"key":"12512_CR25","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1101\/gad.289769.116","volume":"31","author":"E Erdal","year":"2017","unstructured":"Erdal E, Haider S, Rehwinkel J, Harris A, McHugh P (2017) A prosurvival DNA damage-induced cytoplasmic interferon response is mediated by end resection factors and is limited by Trex1. Genes Dev 31:353\u2013369","journal-title":"Genes Dev"},{"key":"12512_CR26","doi-asserted-by":"publisher","unstructured":"Sistigu AYT, Vacchelli E, Chaba K et al (2014) Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 20(11):1301-9. https:\/\/doi.org\/10.1038\/nm.3708","DOI":"10.1038\/nm.3708"},{"issue":"3","key":"12512_CR27","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10549-020-05646-x","volume":"181","author":"AIJC Aljohani","year":"2020","unstructured":"Aljohani AIJC, Kurozumi S, Mohammed OJ, Miligy IM, Green AR, Rakha EA (2020) Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer. Breast Cancer Res Treat 181(3):541\u2013551. https:\/\/doi.org\/10.1007\/s10549-020-05646-x Epub 2020 Apr 29. PMID: 32350677; PMCID: PMC7220876","journal-title":"Breast Cancer Res Treat"},{"issue":"14","key":"12512_CR28","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1158\/1078-0432.CCR-17-2551","volume":"24","author":"AEM Post","year":"2018","unstructured":"Post AEM, Smid M, Nagelkerke A, Martens JWM, Bussink J, Sweep FCGJ et al (2018) Interferon-Stimulated Genes Are Involved in Cross-resistance to Radiotherapy in Tamoxifen-Resistant Breast Cancer. Clin Cancer Res 24(14):3397\u20133408","journal-title":"Clin Cancer Res"},{"key":"12512_CR29","doi-asserted-by":"crossref","unstructured":"Magbanua MJM, Wolf DM, Yau C, Davis SE, Crothers J, Au A et al (2015) Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response. Breast Cancer Res 17(1):73.","DOI":"10.1186\/s13058-015-0582-3"},{"key":"12512_CR30","doi-asserted-by":"crossref","unstructured":"Chao SHXW, Jingping LI, Shang WU, Zhihui LI, Xiaofei RE, Yunjiang LI (2024) IFIH1 promotes apoptosis through the TBK1\/IRF3 pathway in triple-negative breast cancer. Neoplasma 71(6)","DOI":"10.4149\/neo_2024_240614N255"},{"issue":"2","key":"12512_CR31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/bjc.2015.398","volume":"114","author":"MEBI Legrier","year":"2016","unstructured":"Legrier MEBI, Gaston J, Beurdeley A, Yvonnet V, D\u00e9as O, Thuleau A, Ch\u00e2teau-Joubert S, Servely JL, Vacher S, Lassalle M, Depil S, Tucker GC, Fontaine JJ, Poupon MF, Roman-Roman S, Judde JG, Decaudin D, Cairo S, Marangoni E (2016) Activation of IFN\/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer. Br J Cancer 114(2):177\u2013187. https:\/\/doi.org\/10.1038\/bjc.2015.398 Epub 2015 Dec 22. PMID: 26695443; PMCID: PMC4815803","journal-title":"Br J Cancer"},{"key":"12512_CR32","doi-asserted-by":"crossref","unstructured":"Palakurthi B, Fross SR, Guldner IH, Aleksandrovic E, Liu X, Martino AK et al (2023) Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast cancer. Nature Communications 14(1):2109","DOI":"10.1038\/s41467-023-37727-y"},{"key":"12512_CR33","doi-asserted-by":"crossref","unstructured":"Zhang Y, Yu C (2020) Prognostic characterization of OAS1\/OAS2\/OAS3\/OASL in breast cancer. BMC Cancer 20","DOI":"10.1186\/s12885-020-07034-6"},{"issue":"5","key":"12512_CR34","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3390\/biom11050622","volume":"11","author":"M Padariya","year":"2021","unstructured":"Padariya M, Sznarkowska A, Kote S, G\u00f3mez-Herranz M, Mikac S, Pilch M et al (2021) Functional Interfaces, Biological Pathways, and Regulations of Interferon-Related DNA Damage Resistance Signature (IRDS) Genes. Biomolecules 11(5):622","journal-title":"Biomolecules"},{"key":"12512_CR35","doi-asserted-by":"crossref","unstructured":"Liu Y, Yang R, Zhang M, Yang B, Du Y, Feng H et al (2024) Multi-omics landscape of Interferon-stimulated gene OASL reveals a potential biomarker in pan-cancer: from prognosis to tumor microenvironment. Front Immunol 15","DOI":"10.3389\/fimmu.2024.1402951"},{"issue":"1","key":"12512_CR36","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1186\/s12885-020-07034-6","volume":"20","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Yu C (2020) Prognostic characterization of OAS1\/OAS2\/OAS3\/OASL in breast cancer. BMC Cancer 20(1):575","journal-title":"BMC Cancer"},{"key":"12512_CR37","doi-asserted-by":"publisher","first-page":"106916","DOI":"10.1016\/j.intimp.2020.106916","volume":"88","author":"J Zhao","year":"2020","unstructured":"Zhao J, Zhang X, Cheng M, Guan J, Gai J, Fu L et al (2020) Expression of IFN-induced 2\u2032-5\u2032-oligoadenylate synthetases correlates with immune infiltration, revealing potential targets and new biomarkers for basal-like breast cancer prognosis. Int Immunopharmacol 88:106916","journal-title":"Int Immunopharmacol"},{"key":"12512_CR38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.canlet.2021.05.006","volume":"514","author":"O Provance","year":"2021","unstructured":"Provance O, Geanes E, Lui A, Roy A, Holloran S, Gunewardena S et al (2021) Disrupting interferon-alpha and NF-kappaB crosstalk suppresses IFITM1 expression attenuating triple-negative breast cancer progression. Cancer Lett 514:12\u201329","journal-title":"Cancer Lett"},{"key":"12512_CR39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.canlet.2017.04.005","volume":"399","author":"AJGE Lui","year":"2017","unstructured":"Lui AJGE, Ogony J, Behbod F, Marquess J, Valdez K, Jewell W, Tawfik O, Lewis-Wambi J (2017) IFITM1 suppression blocks proliferation and invasion of aromatase inhibitor-resistant breast cancer in vivo by JAK\/STAT-mediated induction of p21. Cancer Lett 399:29\u201343 Epub 2017 Apr 12. PMID: 28411130; PMCID: PMC5530765","journal-title":"Cancer Lett"},{"key":"12512_CR40","doi-asserted-by":"crossref","unstructured":"Choi HJ, Lui A, Ogony J, Jan R, Sims PJ, Lewis-Wambi J (2015) Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death. Breast Cancer Res 17(1):6","DOI":"10.1186\/s13058-014-0506-7"},{"key":"12512_CR41","doi-asserted-by":"crossref","unstructured":"Olivia K, Provance ESG, Asona J, Lui A, Roy SM, Holloran S, Gunewardena CR, Hagan et al (2021) Scott Weir, Joan Lewis-Wambi, Disrupting interferon-alpha and NF-kappaB crosstalk suppresses IFITM1 expression attenuating triple-negative breast cancer progression, Cancer Letters. 514:12\u201329","DOI":"10.1016\/j.canlet.2021.05.006"},{"key":"12512_CR42","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1158\/1078-0432.CCR-19-2405","volume":"26","author":"R Powles","year":"2020","unstructured":"Powles R, Wali V, Li X, Barlow W, Nahleh Z, Thompson A et al (2020) Analysis of Pre- and Posttreatment Tissues from the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome. Clin Cancer Res 26:1977\u20131984","journal-title":"Clin Cancer Res"},{"key":"12512_CR43","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/cncr.34618","volume":"129","author":"J Jin","year":"2023","unstructured":"Jin J, Cao J, Li B, Li T, Zhang J, Cao J et al (2023) Landscape of DNA damage response gene alterations in breast cancer: A comprehensive investigation. Cancer 129:845\u2013859","journal-title":"Cancer"},{"key":"12512_CR44","doi-asserted-by":"crossref","unstructured":"Hwang SH, Baek S, Lee M, Kook Y, Bae S, Ahn S et al (2024) Clinical Relevance of TP53 Mutation and Its Characteristics in Breast Cancer with Long-Term Follow-Up Date. Cancers 16","DOI":"10.3390\/cancers16233899"},{"key":"12512_CR45","unstructured":"Kandioler-Eckersberger DLC, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbauer-Wadl H, Mittlb\u00f6ck M, Gnant M, Steger G, Jakesz R (2000) TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res (1):50-6."},{"issue":"15","key":"12512_CR46","first-page":"5582","volume":"9","author":"SB-DA Geisler","year":"2003","unstructured":"Geisler SB-DA, Johnsen H, Aas T, Geisler J, Akslen LA, Anker G, L\u00f8nning PE (2003) TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 9(15):5582\u20135588","journal-title":"Clin Cancer Res"},{"key":"12512_CR47","doi-asserted-by":"publisher","first-page":"102785","DOI":"10.1016\/j.ctrv.2024.102785","volume":"129","author":"A Calabrese","year":"2024","unstructured":"Calabrese A, Von Arx C, Tafuti A, Pensabene M, De Laurentiis M (2024) Prevention, diagnosis and clinical management of hereditary breast cancer beyond BRCA1\/2 genes. Cancer Treat Rev 129:102785","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"12512_CR48","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1634\/theoncologist.2009-0243","volume":"15","author":"JAF Lehmann-Che","year":"2010","unstructured":"Lehmann-Che JAF, Desmedt C, Mazouni C, Giacchetti S, Turpin E, Espi\u00e9 M, Plassa LF, Marty M, Bertheau P, Sotiriou C, Piccart M, Symmans WF, Pusztai L, de Th\u00e9 H (2010) Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. Oncologist 15(3):246\u2013252. https:\/\/doi.org\/10.1634\/theoncologist.2009-0243 Epub 2010 Mar 12. PMID: 20228131; PMCID: PMC3227956","journal-title":"Oncologist"},{"key":"12512_CR49","doi-asserted-by":"publisher","unstructured":"Bertheau PL-CJ, Varna M, Dumay A, Poirot B, Porcher R, Turpin E, Plassa LF, de Roquancourt A, Bourstyn E, de Cremoux P, Janin A, Giacchetti S, de Espi\u00e9 M (2013) Th\u00e9 H. p53 in breast cancer subtypes and new insights into response to chemotherapy. Breast Suppl 2:S27-9. https:\/\/doi.org\/10.1016\/j.breast.2013.07.005. PMID: 24074787","DOI":"10.1016\/j.breast.2013.07.005"},{"issue":"12","key":"12512_CR50","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1007\/s43032-024-01666-w","volume":"31","author":"P Pourmasoumi","year":"2024","unstructured":"Pourmasoumi P, Moradi A, Bayat M (2024) BRCA1\/2 mutations and breast\/ovarian cancer risk: A new insights review. Reproductive Sci 31(12):3624\u20133634","journal-title":"Reproductive Sci"},{"issue":"3","key":"12512_CR51","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s10549-014-3206-1","volume":"148","author":"WSA Pfeifer","year":"2014","unstructured":"Pfeifer WSA, Potapova ON, Bessonov AA, Ivantsov AO, Laptiev SA, Zaitseva OA, Yatsuk OS, Matsko DE, Semiglazova TY, Togo AV (2014) Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers. Breast Cancer Res Treat 148(3):675\u2013683","journal-title":"Breast Cancer Res Treat"},{"key":"12512_CR52","doi-asserted-by":"crossref","unstructured":"Caramelo O, Silva C, Caramelo F, Frutuoso C, Pinto L, Almeida-Santos T (2022) Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis. Hereditary Cancer Clin Pract 20(1):34","DOI":"10.1186\/s13053-022-00242-0"},{"issue":"28","key":"12512_CR53","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1200\/JCO.2011.35.2682","volume":"29","author":"B Arun","year":"2011","unstructured":"Arun B, Bayraktar S, Liu DD, Barrera AMG, Atchley D, Pusztai L et al (2011) Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience. J Clin Oncol 29(28):3739\u20133746","journal-title":"J Clin Oncol"},{"issue":"22","key":"12512_CR54","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1200\/JCO.2017.77.2285","volume":"36","author":"PA Fasching","year":"2018","unstructured":"Fasching PA, Loibl S, Hu C, Hart SN, Shimelis H, Moore R et al (2018) BRCA1\/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. J Clin Oncol 36(22):2281\u20132287","journal-title":"J Clin Oncol"},{"issue":"3","key":"12512_CR55","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/tbj.12887","volume":"24","author":"L Bignon","year":"2018","unstructured":"Bignon L, Fricker J-P, Nogues C, Mouret-Fourme E, Stoppa-Lyonnet D, Caron O et al (2018) Efficacy of anthracycline\/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1\/BRCA2 mutation carriers. Breast J 24(3):269\u2013277","journal-title":"Breast J"},{"issue":"3","key":"12512_CR56","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/annonc\/mdu559","volume":"26","author":"CZJ Wang","year":"2015","unstructured":"Wang CZJ, Wang Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y (2015) Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer. Ann Oncol 26(3):523\u2013528","journal-title":"Ann Oncol"},{"key":"12512_CR57","doi-asserted-by":"publisher","first-page":"e11857","DOI":"10.1590\/1414-431x2021e11857","volume":"55","author":"MCGK Kneubil","year":"2022","unstructured":"Kneubil MCGK, Brollo J, Coelho GP, Mandelli J, Orlandin BC, Corso LL, Roesch-Ely M, Henriques JA (2022) Predictive value of DNA repair gene expression for response to neoadjuvant chemotherapy in breast cancer. Braz J Med Biol Res 55:e11857","journal-title":"Braz J Med Biol Res"},{"key":"12512_CR58","doi-asserted-by":"crossref","unstructured":"Lili Zhai SL, Li X, Li H, Gu F, Guo X, Liu F, Zhang X et al (2015) The nuclear expression of poly (ADP-ribose) polymerase-1 (PARP1) in invasive primary breast tumors is associated with chemotherapy sensitivity, Pathology - Research and Practice. 211:130\u2013137","DOI":"10.1016\/j.prp.2014.11.004"},{"issue":"8","key":"12512_CR59","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/PAI.0000000000000124","volume":"23","author":"HA Aiad","year":"2015","unstructured":"Aiad HA, Kandil MAH, El-Tahmody MA, Abulkheir IL, Abulkasem FM, Elmansori AA et al (2015) The Prognostic and Predictive Significance of PARP-1 in Locally Advanced Breast Cancer of Egyptian Patients Receiving Neoadjuvant Chemotherapy. Appl Immunohistochem Mol Morphology 23(8):571\u2013579","journal-title":"Appl Immunohistochem Mol Morphology"},{"key":"12512_CR60","doi-asserted-by":"publisher","unstructured":"Chen BLJ, Dai D et al (2020) PARPBP is a prognostic marker and confers anthracycline resistance to breast cancer. Therapeutic Adv Med Oncol 12. https:\/\/doi.org\/10.1177\/1758835920974212","DOI":"10.1177\/1758835920974212"},{"issue":"42","key":"12512_CR61","doi-asserted-by":"publisher","first-page":"68662","DOI":"10.18632\/oncotarget.11900","volume":"7","author":"PHJ Domagala","year":"2016","unstructured":"Domagala PHJ, Rys J, Byrski T, Cybulski C, Lubinski J (2016) Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers. Oncotarget 7(42):68662\u201368673. https:\/\/doi.org\/10.18632\/oncotarget.11900 PMID: 27626685; PMCID: PMC5356581","journal-title":"Oncotarget"},{"issue":"7","key":"12512_CR62","doi-asserted-by":"publisher","first-page":"7435","DOI":"10.1007\/s11033-012-1576-1","volume":"39","author":"AFW Kolacinska","year":"2012","unstructured":"Kolacinska AFW, Szemraj J, Szymanska B, Borowska-Garganisz E, Nowik M, Chalubinska J, Kubiak R, Pawlowska Z, Blasinska-Morawiec M, Potemski P (2012) Gene expression and pathologic response to neoadjuvant chemotherapy in breast cancer. Mol Biol Rep 39(7):7435\u20137441","journal-title":"Mol Biol Rep"},{"key":"12512_CR63","doi-asserted-by":"crossref","unstructured":"Pham A, Yuan F, Nagathihalli N, Dosch A (2026) Ataxia telangiectasia mutated (ATM) kinase as a predictive biomarker in clinical oncology: implications for a precision treatment approach. Neoplasia (New York, NY) 77","DOI":"10.1016\/j.neo.2026.101309"},{"key":"12512_CR64","doi-asserted-by":"crossref","unstructured":"Stucci L, Intern\u00f2 V, Tucci M, Perrone M, Mannavola F, Palmirotta R et al (2021) The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice. Genes 12","DOI":"10.3390\/genes12050727"},{"key":"12512_CR65","doi-asserted-by":"crossref","unstructured":"Li C, Wang B, Tu J, Liu C, Wang Y, Chen J et al (2024) ATM inhibition enhance immunotherapy by activating STING signaling and augmenting MHC Class I. Cell Death Dis 15","DOI":"10.1038\/s41419-024-06911-3"},{"issue":"12","key":"12512_CR66","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/gtc.12100","volume":"18","author":"Y Watanabe","year":"2013","unstructured":"Watanabe Y, Maeda I, Oikawa R, Wu W, Tsuchiya K, Miyoshi Y et al (2013) Aberrant DNA methylation status of DNA repair genes in breast cancer treated with neoadjuvant chemotherapy. Genes Cells 18(12):1120\u20131130","journal-title":"Genes Cells"},{"issue":"3","key":"12512_CR67","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.3390\/ijms23031665","volume":"23","author":"PSC Ferrari","year":"2022","unstructured":"Ferrari PSC, Ghilli M, Bargagna I, Lorenzini G, Nicolini A (2022) Molecular mechanisms, biomarkers and emerging therapies for chemotherapy resistant TNBC. Int J Mol Sci 23(3):1665","journal-title":"Int J Mol Sci"},{"issue":"40","key":"12512_CR68","doi-asserted-by":"publisher","first-page":"42773","DOI":"10.18632\/oncotarget.6001","volume":"6","author":"PDBA Vici","year":"2015","unstructured":"Vici PDBA, Ercolani C, Pizzuti L, Di Lauro L, Sergi D, Sperati F, Terrenato I, Dattilo R, Botti C, Fabi A, Ramieri MT, Mentuccia L, Marinelli C, Iezzi L, Gamucci T, Natoli C, Vitale I, Barba M, Mottolese M, De Maria R, Maugeri-Sacc\u00e0 M (2015) Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis. Oncotarget 6(40):42773\u201342780. https:\/\/doi.org\/10.18632\/oncotarget.6001 PMID: 26544894; PMCID: PMC4767469","journal-title":"Oncotarget"},{"key":"12512_CR69","doi-asserted-by":"crossref","unstructured":"Zhou Z, Zhou Q (2025) Immunotherapy resistance in triple-negative breast cancer: Molecular mechanisms, tumor microenvironment, and therapeutic implications. Front Oncol 15","DOI":"10.3389\/fonc.2025.1630464"},{"issue":"9","key":"12512_CR70","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/s41419-020-03004-9","volume":"11","author":"SWH Liu","year":"2020","unstructured":"Liu SWH, Li J, Zhang J, Wu J, Li Y, Piao Y, Pan L, Xiang R, Yue S (2020) FZR1 as a novel biomarker for breast cancer neoadjuvant chemotherapy prediction. Cell Death Dis 11(9):804","journal-title":"Cell Death Dis"},{"issue":"1","key":"12512_CR71","doi-asserted-by":"publisher","first-page":"43517","DOI":"10.1038\/srep43517","volume":"7","author":"H Zheng","year":"2017","unstructured":"Zheng H SF, Martin S, Xu X, Deng CX (2017) WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance. Sci Rep 7(1):43517","journal-title":"Sci Rep"},{"issue":"4","key":"12512_CR72","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.molcel.2015.11.006","volume":"60","author":"CTK Dominguez-Brauer","year":"2015","unstructured":"Dominguez-Brauer CTK, Mason JM, Blaser H, Bray MR, Mak TW (2015) Targeting mitosis in cancer: emerging strategies. Mol Cell 60(4):524\u2013536","journal-title":"Mol Cell"},{"issue":"7","key":"12512_CR73","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/jcmm.17716","volume":"27","author":"J Wang","year":"2023","unstructured":"Wang J, Zhang J, Ma Q, Zhang S, Ma F, Su W et al (2023) Influence of cyclin D1 splicing variants expression on breast cancer chemoresistance via CDK4\/CyclinD1-pRB\u2010E2F1 pathway. J Cell Mol Med 27(7):991\u20131005","journal-title":"J Cell Mol Med"},{"issue":"3","key":"12512_CR74","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s10549-014-3121-5","volume":"147","author":"MSK Tanioka","year":"2014","unstructured":"Tanioka MSK, Sudo T, Sakuma T, Kajimoto K, Hirokaga K, Takao S, Negoro S, Minami H, Nakagawa K, Nishio K (2014) Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive\/ER-positive breast cancer. Breast Cancer Res Treat 147(3):513\u2013525","journal-title":"Breast Cancer Res Treat"},{"key":"12512_CR75","doi-asserted-by":"crossref","unstructured":"Hoogstraat MLE, Mayayo-Peralta I, Mulder L, Kristel P, van der Heijden I, Annunziato S, van Seijen M, Nederlof PM, Sonke GS, Zwart W (2022) Comprehensive characterization of pre-and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance. NPJ Breast Cancer 8(1):60","DOI":"10.1038\/s41523-022-00428-8"},{"issue":"8","key":"12512_CR77","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.3390\/cancers15082194","volume":"15","author":"WLE Zhang","year":"2023","unstructured":"Zhang WLE, Wang L, Lehmann BD, Chen XS (2023) Transcriptome meta-analysis of triple-negative breast cancer response to neoadjuvant chemotherapy. Cancers 15(8):2194","journal-title":"Cancers"},{"issue":"7","key":"12512_CR78","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","volume":"13","author":"NC O\u2019leary B FR, Turner","year":"2016","unstructured":"O\u2019leary B FR, Turner NC (2016) Treating cancer with selective CDK4\/6 inhibitors. Nat reviews Clin Oncol 13(7):417\u2013430","journal-title":"Nat reviews Clin Oncol"},{"key":"12512_CR79","doi-asserted-by":"crossref","unstructured":"Zhu JML, Tong W, Borlak J, Chen M (2020) Cancer genomics predicts disease relapse and therapeutic response to neoadjuvant chemotherapy of hormone sensitive breast cancers. Scientific Reports 10(1):8188","DOI":"10.1038\/s41598-020-65055-4"},{"issue":"6","key":"12512_CR80","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.21037\/tcr-22-2807","volume":"12","author":"SZH Zhao","year":"2023","unstructured":"Zhao SZH, Yang N, Yang J (2023) A narrative review about CDK4\/6 inhibitors in the setting of drug resistance: updates on biomarkers and therapeutic strategies in breast cancer. Transl Cancer Res 12(6):1617\u20131634. https:\/\/doi.org\/10.21037\/tcr-22-2807 Epub 2023 Jun 15. PMID: 37434680; PMCID: PMC10331716","journal-title":"Transl Cancer Res"},{"key":"12512_CR81","doi-asserted-by":"crossref","unstructured":"Al-Qasem AJAC, Ditzel HJ (2021) Resistance mechanisms to combined CDK4\/6 inhibitors and endocrine therapy in ER+\/HER2\u2249\u2013 advanced breast cancer: Biomarkers and potential novel treatment strategies. Cancers 13(21):5397","DOI":"10.3390\/cancers13215397"},{"issue":"15","key":"12512_CR82","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.3390\/cancers13153737","volume":"13","author":"PKS Linn","year":"2021","unstructured":"Linn PKS, Sheng J, Kulathunga N, Yu H, Zhang Z, Voon D, Watanabe Y, Takahashi C (2021) Targeting RB1 loss in cancers. Cancers 13(15):3737","journal-title":"Cancers"},{"issue":"14","key":"12512_CR83","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-19-0404","volume":"25","author":"WSAM Chen","year":"2019","unstructured":"Chen WSAM, Zhao SG, Liu Y, Mahal BA, Quigley DA, Wei T, Davicioni E, Rebbeck TR, Kantoff PW, Maher CA (2019) Novel RB1-loss transcriptomic signature is associated with poor clinical outcomes across cancer types. Clin Cancer Res 25(14):4290\u20134299","journal-title":"Clin Cancer Res"},{"issue":"18","key":"12512_CR84","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1158\/1078-0432.CCR-12-0903","volume":"18","author":"AKEA Witkiewicz","year":"2012","unstructured":"Witkiewicz AKEA, McFalls J, Valsecchi ME, Schwartz G, Knudsen ES (2012) RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 18(18):5110\u20135122","journal-title":"Clin Cancer Res"},{"key":"12512_CR85","doi-asserted-by":"publisher","first-page":"175883591989160","DOI":"10.1177\/1758835919891608","volume":"11","author":"EBC Risi","year":"2019","unstructured":"Risi EBC, Benelli M, Migliaccio I, McCartney A, Bonechi M, Guarducci C, Hilbers F, Di Cosimo S, Huober J, Romagnoli D (2019) An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1\u201306). Therapeutic Adv Med Oncol 11:1758835919891608","journal-title":"Therapeutic Adv Med Oncol"},{"issue":"7","key":"12512_CR86","doi-asserted-by":"publisher","first-page":"7829","DOI":"10.18632\/oncotarget.6953","volume":"7","author":"NVCN Litviakov","year":"2016","unstructured":"Litviakov NVCN, Tsyganov MM, Slonimskaya EM, Ibragimova MK, Kazantseva PV, Kzhyshkowska J, Choinzonov EL (2016) Deletions of multidrug resistance gene loci in breast cancer leads to the down-regulation of its expression and predict tumor response to neoadjuvant chemotherapy. Oncotarget 7(7):7829\u20137841. https:\/\/doi.org\/10.18632\/oncotarget.6953 PMID: 26799285; PMCID: PMC4884957","journal-title":"Oncotarget"},{"issue":"8","key":"12512_CR87","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.3390\/cancers12082012","volume":"12","author":"MR Chica-Parrado","year":"2020","unstructured":"Chica-Parrado MR, G-OA, Jim\u00e9nez B, Ribelles N, Barragan I, Alba E (2020) Resistance to neoadjuvant treatment in breast cancer: clinicopathological and molecular predictors. Cancers 12(8):2012","journal-title":"Cancers"},{"issue":"8","key":"12512_CR88","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41389-021-00347-6","volume":"10","author":"CAN Ashok","year":"2021","unstructured":"Ashok CAN, Natua S, Mishra J, Samaiya A, Shukla S (2021) E2F1 and epigenetic modifiers orchestrate breast cancer progression by regulating oxygen-dependent ESRP1 expression. Oncogenesis 10(8):58","journal-title":"Oncogenesis"},{"issue":"7","key":"12512_CR89","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.3390\/cells9071643","volume":"9","author":"MTH Oshi","year":"2020","unstructured":"Oshi MTH, Tokumaru Y, Yan L, Rashid OM, Nagahashi M, Matsuyama R, Endo I, Takabe K (2020) The E2F pathway score as a predictive biomarker of response to neoadjuvant therapy in ER+\/HER2\u2249\u2013 breast cancer. Cells 9(7):1643","journal-title":"Cells"},{"issue":"24","key":"12512_CR90","doi-asserted-by":"publisher","first-page":"6039","DOI":"10.1158\/1078-0432.CCR-16-0471","volume":"22","author":"DGCJ Stover","year":"2016","unstructured":"Stover DGCJ, Barry WT, Brugge JS, Winer EP, Selfors LM (2016) The role of proliferation in determining response to neoadjuvant chemotherapy in breast cancer: A gene expression\u2013based meta-analysis. Clin Cancer Res 22(24):6039\u20136050","journal-title":"Clin Cancer Res"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12512-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12512-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12512-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:05:07Z","timestamp":1785438307000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12512-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12512"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12512-4","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"27 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is a narrative review and does not involve human participants, animal experiments, or clinical interventions.","order":2,"name":"Ethics","label":"Ethics declaration","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1305"}}